Opinion|Videos|January 31, 2025

Novel Intravitreal Injections: Faricimab and Aflibercept 8mg for the Treatment of Retinal Diseases

Panelists discuss how novel intravitreal agents faricimab and high-dose aflibercept 8mg offer potential advantages in treating retinal diseases through their extended durability and dual mechanism of action.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.


Latest CME